NDRA - ENDRA Life Sciences Inc. EV/EBITDA Multiple

ENDRA Life Sciences (NDRA) exhibits a high dependency on the success of a single product, which creates risks during a prolonged market rollout of the technology. This price chart, illustrating trading dynamics with an EV/EBITDA metric of 0.00, complements the business analysis. The company is implementing ultrasound modules for the early detection of steatosis, creating a stable revenue stream from consumables. The innovative TAEUS method is designed to serve as an accessible primary screen prior to costly MRI scans.

When constructing a defensive portfolio, fundamental screening requires accounting for debt load by comparing the total enterprise value to operating profit before depreciation and interest. This ratio determines the asset payback period, where a decrease in value signals undervaluation and an increase indicates the asset is overbought. For ENDRA Life Sciences (NDRA), which is developing thermoacoustic liver diagnostics, the company's dynamic EV/EBITDA ratio reflects the market value of its innovations relative to current business efficiency.